Sensus Healthcare (NASDAQ:SRTS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Sensus Healthcare (NASDAQ:SRTS) had its target price boosted by analysts at HC Wainwright from $10.00 to $11.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 31.50% from the company’s current price. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, FY2024 earnings at $0.42 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group lifted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Stock Down 0.5 %

SRTS stock opened at $8.37 on Monday. The stock’s 50 day moving average is $6.42 and its two-hundred day moving average is $6.00. Sensus Healthcare has a 52-week low of $2.02 and a 52-week high of $8.69. The company has a market capitalization of $137.10 million, a PE ratio of 14.75 and a beta of 1.04.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after acquiring an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after purchasing an additional 11,525 shares during the period. Sachetta LLC lifted its position in shares of Sensus Healthcare by 12.9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after buying an additional 13,544 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Sensus Healthcare by 152.4% in the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after buying an additional 46,732 shares during the period. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.